⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL17255283 | 0.73 | — | — | |
| Trifluoroacetic Acid SCHEMBL29589461 | 0.73 | — | — | |
| Trifluoroacetic Acid SCHEMBL31579729 | 0.70 | SLC6A2 (0.32) | — | |
| SCHEMBL20975403 | 0.69 | CRBN (0.32) | — | |
| Trifluoroacetic Acid SCHEMBL25302794 | 0.69 | — | — | |
| Trifluoroacetic Acid SCHEMBL29657439 | 0.69 | CRBN (0.33) | — | |
| Trifluoroacetic Acid SCHEMBL21590640 | 0.68 | — | — | |
| Trifluoroacetic Acid SCHEMBL32683623 | 0.68 | — | — | |
| Trifluoroacetic Acid SCHEMBL20958677 | 0.67 | PKM (0.32) | — | |
| Trifluoroacetic Acid SCHEMBL31439473 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2025104154-A1 | 5-[2,7-DIAZASPIRO[3.5]NONAN-7-YL]-5-[4-PHENOXYPHENYL]HEXAHYDROPYRIMIDINE-2,4,6-TRIONE DERIVATIVES AS MMP9 INHIBITORS FOR THE TREATMENT OF DRY EYE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-05-22 | — | — | WO | disclosed |
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC | 2023-06-08 | — | — | US | disclosed |
| US-11479557-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2022-10-25 | — | — | US | disclosed |
| CN-109743875-B | Inhibitors of the MENIN-MLL interaction | 生命医药有限责任公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3805215-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20210053974-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2021-02-25 | — | — | US | disclosed |
| EP-3468966-B1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10683302-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190144459-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC | 2019-05-16 | — | — | US | disclosed |